Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Stein

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
Lancet (London, England)|October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trialJ Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
Cancers|September 10, 2021
Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data AnalysisLouisa Hempel, Julia Veloso de Oliveira, Andreas Gaumann, et al.
British Journal of Cancer|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study GroupIsabella C Wiest, Lena Dreikhausen, Ralph Keller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDHans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Plos One|June 14, 2024
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trialThomas Seufferlein, Ludwig Lausser, Alexander Stein, et al.
Frontiers in Oncology|November 1, 2023
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, et al.
British Journal of Cancer|November 23, 2023
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialHans-Joachim Schmoll, Julia Mann, Fabian Meinert, et al.
Cancer Immunology Research|September 19, 2022
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple MyelomaCarlotta Welters, María Fernanda Lammoglia Cobo, Christian Alexander Stein, et al.
Med (New York, N.Y.)|April 12, 2025
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trialAnna Brandt, Konrad Klinghammer, Christoph Schultheiss, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|August 21, 2020
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trialVivek Subbiah, Ulrik Lassen, Elena Élez, et al.
Lancet (London, England)|October 23, 2025
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trialJ Randolph Hecht, Young Suk Park, Josep Tabernero, et al.
Cancers|September 10, 2021
Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach-A Real World Data AnalysisLouisa Hempel, Julia Veloso de Oliveira, Andreas Gaumann, et al.
British Journal of Cancer|May 19, 2026
Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study GroupIsabella C Wiest, Lena Dreikhausen, Ralph Keller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2020
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDHans-Joachim Schmoll, Alexander Stein, Eric Van Cutsem, et al.
Plos One|June 14, 2024
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trialThomas Seufferlein, Ludwig Lausser, Alexander Stein, et al.
Frontiers in Oncology|November 1, 2023
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321)Joseph Tintelnot, Alexander Stein, Salah-Eddin Al-Batran, et al.
British Journal of Cancer|November 23, 2023
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trialHans-Joachim Schmoll, Julia Mann, Fabian Meinert, et al.
Cancer Immunology Research|September 19, 2022
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple MyelomaCarlotta Welters, María Fernanda Lammoglia Cobo, Christian Alexander Stein, et al.
Med (New York, N.Y.)|April 12, 2025
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trialAnna Brandt, Konrad Klinghammer, Christoph Schultheiss, et al.
Pageof 15